Evaluating Macular Edema After AcF Implant Injection
Evaluation of Diabetic or Uveitic Macular Edema After Injection of a Fluocinolone Acetonide (AcF) Implant 1 Month After the Last Dexamethasone (DXM) Implant: Evaluation at 3 Years
This study is testing a new eye implant to see if it can help people with diabetic macular edema or uveitis-related macular edema who haven't improved with other treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 34 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nantes University Hospital Academic / other |
| Locations | 1 site (Nantes) |
| Trial ID | NCT05996822 on ClinicalTrials.gov |
What this trial studies
This study evaluates patients with diabetic macular edema or uveitis-related macular edema who have not responded to first-line treatments. Participants will receive an intravitreal injection of a fluocinolone acetonide (AcF) implant one month after a dexamethasone (DXM) implant. The study aims to assess the safety and efficacy of AcF, which provides longer-lasting corticosteroid delivery compared to DXM. The goal is to understand the therapeutic outcomes and potential need for additional treatments during the AcF active period.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with diabetic macular edema or uveitis-related macular edema who have previously received a DXM injection.
Not a fit: Patients who refuse to allow their medical data to be used for research purposes will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective long-term treatment option for patients with macular edema.
How similar studies have performed: Previous studies have shown success with similar approaches, particularly with the AcF implant in managing macular edema.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient (Male, Female)°≥ 18 years old * Having received an AcF injection 1 month after a DXM injection * For diabetic macular edema or uveitic macular edema Exclusion Criteria: * Patient's refusal to allow his or her medical data to be used for research purposes
Where this trial is running
Nantes
- Jean-Baptiste Ducloyer — Nantes, France (Recruiting)
Study contacts
- Study coordinator: Jean-Baptiste Ducloyer, M.D
- Email: jeanbaptiste.ducloyer@chu-nantes.fr
- Phone: 0253482857
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.